A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Glembatumumab vedotin (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms METRIC
- Sponsors Celldex Therapeutics Inc
- 14 Mar 2017 According to a Celldex Therapeutics media release, an enrollment will be completed by the end of September 2017.
- 03 Feb 2017 This trial has been discontinued in Austria.
- 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.